The influence of modifications in imide fragment structure on 5-HT1A and 5-HT7 receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 22, 2007, Pages 7116-7125

  Paluchowska, Maria H ^a   Bugno, Ryszard ^a   Duszyńska, Beata ^a   Tatarczyńska, Ewa ^a   Nikiforuk, Agnieszka ^a   Lenda, Tomasz ^a   Chojnacka Wójcik, Ewa ^a  

^a Polska Akademia Nauk Oddzial w Krakowie   (Poland)

Author keywords

5 HT1A and 5 HT7 receptor ligands; 5 HT1A receptor agonists; Anxiolytic and antidepressant like activity; Arylpiperazines; Structure intrinsic activity relationships studies

Indexed keywords

1 [4 [4 (3 TRIFLUOROMETHYLPHENYL)PIPERAZIN 1 YL]BUTYL]PIPERIDINE 2,6 DIONE; 1 [4 [4 (3 TRIFLUOROMETHYLPHENYL)PIPERAZIN 1 YL]CYCLOHEXYL]PIPERIDINE 2,6 DIONE; 2 [4 [4 ( TRIFLUOROMETHYLPHENYL)PIPERAZIN 1 YL]BUTYL] 2,3,3A,4,7,7A HEXAHYDRO 1H ISOINDOLE 1,3 DIONE; 2 [4 [4 (3 TRIFLUOROMETHYLPHENYL)PIPERAZIN 1 YL]BUTYL] 2,3,4,5,6,7 HEXAHYDRO 1H ISOINDOLE 1,3 DIONE; 2 [4 [4 (3 TRIFLUOROMETHYLPHENYL)PIPERAZIN 1 YL]CYCLOHEXYL] 2,3,3A,4,7,7A HEXAHYDRO 1H ISOINDOLE 1,3 DIONE; 2 [4 [4 (3 TRIFLUOROMETHYLPHENYL)PIPERAZIN 1 YL]CYCLOHEXYL] 2,3,4,5,6,7 HEXAHYDRO 1H ISOINDOLE 1,3 DIONE; 3,4 DIMETHYL 1 [4 [4 (3 TRIFLUOROMETHYLPHENYL)PIPERAZIN 1 YL]BUTYL] 3 PYRROLINE 2,5 DIONE; 3,4 DIMETHYL 1 [4 [4 (3 TRIFLUOROMETHYLPHENYL)PIPERAZIN 1 YL]CYCLOHEXYL] 3 PYRROLINE 2,5 DIONE; DIAZEPAM; DOPAMINE 2 RECEPTOR; GLUTARIMIDE DERIVATIVE; IMIPRAMINE; PIPERAZINE DERIVATIVE; SEROTONIN 1A RECEPTOR; SEROTONIN 7 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG ACTIVITY; EMBRYO; HUMAN; HUMAN CELL; IN VIVO STUDY; LOCOMOTION; MALE; MOUSE; NONHUMAN; RAT; RECEPTOR AFFINITY; SWIMMING; TRANQUILIZING ACTIVITY;

ANIMALS; BODY TEMPERATURE; CELL LINE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; IMIDES; LIGANDS; LIP; MAZE LEARNING; MICE; MOLECULAR STRUCTURE; MOTOR ACTIVITY; PIPERAZINES; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, SEROTONIN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SWIMMING;

MUS;

EID: 34548838847     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.07.029     Document Type: Article

References (32)

1. Paluchowska M.H., Mokrosz M.J., Bojarski A., Wesołowska A., Borycz J., Charakchieva-Minol S., and Chojnacka-Wójcik E. J. Med. Chem. 42 (1999) 4952
2. Bojarski A.J., Paluchowska M.H., Duszyńska B., Kłodzińska A., Tatarczyńska E., and Chojnacka-Wójcik E. Bioorg. Med. Chem. 13 (2005) 2293
3. Paluchowska M.H., Bugno R., Bojarski A.J., Charakchieva-Minol S., Duszyńska B., Tatarczyńska E., Kłodzińska A., Stachowicz K., and Chojnacka-Wójcik E. Bioorg. Med. Chem. 13 (2005) 1195
4. Bojarski A.J., Paluchowska M.H., Duszyńska B., Bugno R., Kłodzińska A., Tatarczyńska E., and Chojnacka-Wójcik E. Bioorg. Med. Chem. 14 (2006) 1391
5. Nowak M., Kołaczkowski M., Pawłowski M., and Bojarski A.J. J. Med. Chem. 49 (2006) 205
6. Wesołowska A., Paluchowska M.H., and Chojnacka-Wójcik E. Eur. J. Pharmacol. 471 (2003) 27
7. López-Rodri{dotless}́guez M.L., Morcillo M.J., Rovat T.K., Fernández E., Vicente B., Sanz A.M., Hernández M., and Orensanz L. J. Med. Chem. 42 (1999) 36
8. Paluchowska M.H., Bojarski A.J., Charakchieva-Minol S., and Wesołowska A. Eur. J. Med. Chem. 37 (2002) 273
9. Goodwin G.M., De Souza R.J., and Green A.R. Neuropharmacology 24 (1985) 1187
10. Martin K.F., and Heal D.J. In: Fozard J.R., and Saxena P.R. (Eds). Molecular Biology, Receptors and Functional Effects (1991), Birkhäuser, Basel 483-490
11. Forster E.A., Cliffe I.A., Bill D.J., Dover G.M., Jones D., Reilly Y., and Fletcher A. Eur. J. Pharmacol. 281 (1995) 81
12. Mokrosz J.L., Paluchowska M.H., Chojnacka-Wójcik E., Filip M., Charakchieva-Minol S., Dereń-Wesołek A., and Mokrosz M.J. J. Med. Chem. 37 (1994) 2754
13. Berendsen H.H.G., Jenck F., and Broekkamp C.L.E. Pharmacol. Biochem. Behav. 33 (1989) 821
14. Berendsen H.H.G., Broekkamp C.L.E., and Van Delft A.M. Behav. Neural. Biol. 55 (1991) 214
15. Przegaliński E., Filip M., Budziszewska B., and Chojnacka-Wójcik E. Pol. J. Pharmacol. 46 (1994) 21
16. Aron C., Simon P., Larousse C., and Boissier J.R. Neuropharmacology 10 (1971) 459
17. Porsolt R.D., Bertin A., and Jalfre M. Arch. Int. Pharmacodyn. Ther. 229 (1977) 327
18. De Vry J. Psychopharmacol. 121 (1995) 1
19. Handley S.L. Pharmacol. Ther. 66 (1995) 103
20. López-Rubalcava C. Pharmacol. Biochem. Behav. 54 (1996) 677
21. Przegaliński E., Tatarczyńska E., Kłodzińska A., and Chojnacka-Wójcik E. Neuropharmacology 33 (1994) 1109
22. Chojnacka-Wójcik E., Tatarczyńska E., Gołembiowska K., and Przegaliński E. Neuropharmacology 30 (1991) 711
23. Tatarczyńska E., Kłodzińska A., Stachowicz K., and Chojnacka-Wójcik E. Behav. Pharmacol. 15 (2004) 523
24. Wesołowska A., Nikiforuk A., Stachowicz K., and Tatarczyńska E. Neuropharmacology 51 (2006) 578
25. Wesołowska A., Nikiforuk A., and Stachowicz K. Eur. J. Pharmacol. 553 (2006) 185
26. Griebel G., Rodgers R.J., Perrault G., and Sanger D.J. Psychopharmacology 121 (1999) 121
27. Griebel G., Rodgers R.J., Perrault G., and Sanger D.J. Neuropharmacology 39 (2000) 1848
28. Anden N.E., Pauksens K., and Svensson K. J. Neural. Transm. 55 (1982) 111
29. Cheng Y., and Prusoff W.H. Biochem. Pharmacol. 22 (1973) 3099
30. Bojarski A.J., Cegła M.T., Charakchieva-Minol S., Mokrosz M.J., Maćkowiak M., and Mokrosz J.L. Pharmazie 48 (1993) 289
31. Mokrosz J.L., Duszyńska B., Charakchieva-Minol S., Bojarski A.J., Mokrosz M.J., Wydra R.L., Janda L., and Strekowski L. Eur. J. Med. Chem. 31 (1996) 973
32. Thomas D.R., Gittins S.A., Collin L.L., Middlemiss D.N., Riley G., Hagan J., Gloger I., Ellis C.E., Forbes I.T., and Brown A.M. Br. J. Pharmacol. 124 (1998) 1300